Rami Komrokji, MD

Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.

The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data.

Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.

Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy.

Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies.

Experts in lower-risk myelodysplastic syndromes analyze and interpret the comparative biomarker data on ring sideroblasts in LR-MDS patients from the COMMANDS study.

The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

A key opinion leader offers insights and analysis on the recently presented COMMANDS trial data from the European Hematology Association 2024 conference.

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.

Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.

The expert panel in hematology examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

A panel of expert hematologists give an overview of myelodysplastic syndrome, focusing on diagnosis, classification, and treatment practices.

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.